Page 25 - Morphosys This News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morphosys this. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morphosys This Today - Breaking & Trending Today

The Goldman Sachs Group Analysts Give MorphoSys (ETR:MOR) a €24.00 Price Target

MorphoSys (ETR:MOR – Get Rating) has been given a €24.00 ($25.81) price target by stock analysts at The Goldman Sachs Group in a research report issued on Friday, Borsen Zeitung reports. The Goldman Sachs Group’s target price points to a potential upside of 15.33% from the company’s current price. Several other brokerages also recently weighed […] ....

United States , Borsen Zeitung , Berenberg Bank , Deutsche Bank Rese , Deutsche Bank Aktiengesellschaft , Jpmorgan Chase Co , Morphosys Company Profile Get Rating , Goldman Sachs Group , Get Rating , Bank Aktiengesellschaft , Bank Rese , Sys Company Profile , Petr Mor , Set Price Target , The Goldman Sachs Group Inc ,

MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022

New translational data suggests potential disease-modifying effects following treatment with pelabresib of both first-line and ruxolitinib-relapsed/refractory patients A comparative model suggests ....

New York , United States , Thomas Biegi , Julia Neugebauer , John Mascarenhas , Eamonn Nolan , Myles Clouston , Development Officer , Adult Leukemia Program , European Hematology Association , Constellation Pharmaceuticals Inc , Tisch Cancer Institute At Mount Sinai , Exchange Commission , Hybrid Congress , Tisch Cancer Institute , Mount Sinai , Malte Peters , Morphosys Chief Research , Morphosy Annual Report ,

MorphoSys (ETR:MOR) PT Set at €65.00 by Berenberg Bank

MorphoSys (ETR:MOR – Get Rating) has been assigned a €65.00 ($69.15) target price by equities researchers at Berenberg Bank in a research report issued on Friday, Borsen Zeitung reports. Berenberg Bank’s target price would indicate a potential upside of 224.51% from the company’s previous close. Several other equities analysts also recently commented on the stock. […] ....

United States , Borsen Zeitung , Jpmorgan Chase Co , Berenberg Bank , Deutsche Bank Rese , Deutsche Bank Aktiengesellschaft , Get Rating , Bank Aktiengesellschaft , Bank Rese , Petr Mor , Set Price Target ,

MorphoSys (NASDAQ:MOR) Lowered to Hold at Zacks Investment Research

MorphoSys (NASDAQ:MOR – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Saturday, Zacks.com reports. According to Zacks, “MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company’s proprietary portfolio consists of MOR208, MOR202, MOR103, […] ....

United States , Capricorn Fund Managers Ltd , Morgan Stanley , Berenberg Bank , Goldman Sachs Group Inc , Zacks Investment Research , Deutsche Bank Aktiengesellschaft , Susquehanna International Group , Alphacentric Advisors , Morphosys Company Profile Get Rating , Millennium Management , Get Rating , Fund Managers Ltd , Centric Advisors , Sachs Group , International Group , Sys Company Profile , Nasdaq Mor ,

MorphoSys (NASDAQ:MOR) Given New €37.00 Price Target at Morgan Stanley

MorphoSys (NASDAQ:MOR – Get Rating) had its price target decreased by equities research analysts at Morgan Stanley from €40.00 ($41.67) to €37.00 ($38.54) in a research report issued to clients and investors on Friday, The Fly reports. The brokerage currently has an “equal weight” rating on the stock. MOR has been the topic of a […] ....

United States , Capricorn Fund Managers Ltd , Morgan Stanley , Berenberg Bank , Zacks Investment Research , Deutsche Bank Aktiengesellschaft , Quadrant Capital Group , Cubist Systematic Strategies , Us Bancorp , Get Rating , Investment Research , Bank Aktiengesellschaft , Capital Group , Systematic Strategies , Nasdaq Mor , Lower Price Target ,